These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The clinical pharmacology and dynamics of marihuana cigarette smoking. Perez-Reyes M; Owens SM; Di Guiseppi S J Clin Pharmacol; 1981; 21(S1):201S-207S. PubMed ID: 6271825 [TBL] [Abstract][Full Text] [Related]
4. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Brenneisen R; Meyer P; Chtioui H; Saugy M; Kamber M Anal Bioanal Chem; 2010 Apr; 396(7):2493-502. PubMed ID: 20112012 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159 [TBL] [Abstract][Full Text] [Related]
6. Effects of delta 9-THC on marijuana smoking, dose choice, and verbal report of drug liking. Kelly TH; Foltin RW; Emurian CS; Fischman MW J Exp Anal Behav; 1994 Mar; 61(2):203-11. PubMed ID: 8169569 [TBL] [Abstract][Full Text] [Related]
7. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Lindgren JE; Ohlsson A; Agurell S; Hollister L; Gillespie H Psychopharmacology (Berl); 1981; 74(3):208-12. PubMed ID: 6267648 [TBL] [Abstract][Full Text] [Related]
8. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach. Awasthi R; An G; Donovan MD; Boles Ponto LL J Pharm Sci; 2018 Feb; 107(2):745-755. PubMed ID: 28942005 [TBL] [Abstract][Full Text] [Related]
9. Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. Hunault CC; van Eijkeren JC; Mensinga TT; de Vries I; Leenders ME; Meulenbelt J Toxicol Appl Pharmacol; 2010 Aug; 246(3):148-53. PubMed ID: 20450927 [TBL] [Abstract][Full Text] [Related]
10. Kinetic study of smoking marijuana. Barnett G; Chiang CW; Perez-Reyes M; Owens SM J Pharmacokinet Biopharm; 1982 Oct; 10(5):495-506. PubMed ID: 6300367 [TBL] [Abstract][Full Text] [Related]
11. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). Huestis MA; Henningfield JE; Cone EJ J Anal Toxicol; 1992; 16(5):283-90. PubMed ID: 1338216 [TBL] [Abstract][Full Text] [Related]
12. Are choice and self-administration of marijuana related to delta 9-THC content? Kelly TH; Foltin RW; Emurian CS; Fischman MW Exp Clin Psychopharmacol; 1997 Feb; 5(1):74-82. PubMed ID: 9234042 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. Sempio C; Huestis MA; Mikulich-Gilbertson SK; Klawitter J; Christians U; Henthorn TK Br J Clin Pharmacol; 2020 Mar; 86(3):611-619. PubMed ID: 31747464 [TBL] [Abstract][Full Text] [Related]
14. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. Huestis MA; Henningfield JE; Cone EJ J Anal Toxicol; 1992; 16(5):276-82. PubMed ID: 1338215 [TBL] [Abstract][Full Text] [Related]
15. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. McBurney LJ; Bobbie BA; Sepp LA J Anal Toxicol; 1986; 10(2):56-64. PubMed ID: 3009969 [TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of marihuana cigarettes to three different potencies. Perez-Reyes M; Di Guiseppi S; Davis KH; Schindler VH; Cook CE Clin Pharmacol Ther; 1982 May; 31(5):617-24. PubMed ID: 6280918 [TBL] [Abstract][Full Text] [Related]
17. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Johansson E; Halldin MM; Agurell S; Hollister LE; Gillespie HK Eur J Clin Pharmacol; 1989; 37(3):273-7. PubMed ID: 2558889 [TBL] [Abstract][Full Text] [Related]
18. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum. Bonnet U; Borda T; Scherbaum N; Specka M Drug Alcohol Depend; 2015 Oct; 155():302-6. PubMed ID: 26298553 [TBL] [Abstract][Full Text] [Related]
19. Concentration and particle size distribution in smoke from marijuana cigarettes with different delta 9-tetrahydrocannabinol content. Hiller FC; Wilson FJ; Mazumder MK; Wilson JD; Bone RC Fundam Appl Toxicol; 1984 Jun; 4(3 Pt 1):451-4. PubMed ID: 6086435 [TBL] [Abstract][Full Text] [Related]
20. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Heishman SJ; Huestis MA; Henningfield JE; Cone EJ Pharmacol Biochem Behav; 1990 Nov; 37(3):561-5. PubMed ID: 1965045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]